jiliko casino online

NoneYankees get closer Devin Williams from Brewers for Nestor Cortes, Caleb Durbin

Syria's Druze hope for better future without Assad

49ers QB Brock Purdy, DE Nick Bosa out, Brandon Allen to start at Green BayNone

Travis Hunter and Ashton Jeanty give this year's Heisman Trophy ceremony a different vibe

The Nashville Predators have worked plenty of overtime lately but have yet to be rewarded. They will try to escape their rut when they visit the Toronto Maple Leafs on Wednesday night. Nashville has lost three straight games 3-2 in overtime. Its latest sudden-death setback came on Saturday at Minnesota in the opener of a four-game road swing. The trip moves to three Canadian cities, with games against the Maple Leafs, the Montreal Canadiens and the Ottawa Senators on tap. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Planet Reports Financial Results for Third Quarter of Fiscal Year 2025CÎROC Champions Creative Ease with the 'Blue Dot Creative Residency': An Innovative Program Empowering Emerging StorytellersPRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sale of an aggregate of 1,085,325 shares of its common stock (or common stock equivalents in lieu thereof) (the "Registered Direct Shares”) and warrants to purchase up to an aggregate of 1,085,325 shares of common stock (the "Registered Direct Warrants”), in a registered direct offering. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold in the registered direct offering together with one common warrant at a combined offering price of $2.23, priced at-the-market under the rules of the Nasdaq Stock Market. The Registered Direct Warrants will have an exercise price of $2.10 per share, are immediately exercisable and will expire five years from the date of issuance. The Company has also entered into a definitive agreement with an existing investor, in a concurrent private placement, for the purchase and sale of an aggregate of 673,000 shares of its common stock (or common stock equivalents in lieu thereof) (the "PIPE Shares”) and warrants to purchase up to an aggregate of 673,000 shares of common stock (the "PIPE Warrants”). Each share of common stock (or pre-funded warrant in lieu thereof) is being sold in the private placement offering together with one common warrant at a combined offering price of $2.23, priced at-the-market under the rules of the Nasdaq Stock Market. The PIPE Warrants will have an exercise price of $2.10 per share, are immediately exercisable and will expire five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about December 10, 2024, subject to the satisfaction of customary closing conditions. Chardan is acting as the exclusive placement agent for the registered direct offering and the concurrent private placement. The gross proceeds to the Company from the registered direct offering and the concurrent private placement are expected to be approximately $3.9 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for research and development, including clinical trials, working capital and general corporate purposes. The Registered Direct Shares are being offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form S-3 (File No. 333-251406) that was originally filed with the Securities and Exchange Commission (the "SEC") on December 22, 2023, and declared effective on January 4, 2024. The offering of such securities in the registered direct offering is being made only by means of a prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained, when available, from Chardan Capital Markets, LLC, 17 State Street, Suite 2130, New York, New York 10004, at (646) 465-9000, or by email at [email protected] . The PIPE Shares, the PIPE Warrants and the Registered Direct Warrants and the shares underlying the PIPE Warrants and the Registered Direct Warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act, or applicable state securities laws. Accordingly, the PIPE Shares, the PIPE Warrants, the Registered Direct Warrants and the shares of common stock underlying the PIPE Warrants and the Registered Direct Warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as F H AB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's F H AB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. F H AB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the closing of the registered direct offering and the concurrent private placement and the expected use of proceeds, the outcome of the Company's clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Relations Contact: JTC Team, LLC Jenene Thomas 908.824.0775 [email protected] Source: Sonnet BioTherapeutics Holdings, Inc.A hairstylist’s assist, ‘divine intervention’ and $2.2 million for Inola High School

None

Texas files first lawsuit against out-of-state abortion provider

All Self-Service Bounty Clearance Kiosk locations in Starfield

ISLAMABAD: Senator Faisal Vawda hinted at the removal of one of the provincial governors very soon. Speaking during the ARY News program, Senator Faisla Vawda said on Friday, “A provincial governor will be in troubled waters soon and his time is up. Without mentioning the name, Faisla Vawda said the governor in question has been selling his name, making money, and telling lies, now his turn has come, and he has to go home soon”. Vawda predicted that the governor’s removal would occur within the next week or two months but he will surely be removed from his post. He also took the opportunity to criticize the PPP-led Sindh government, stating that none of its cabinet members, aside from Chief Minister Murad Ali Shah, are capable of writing a paragraph in English. Vawda added that only god can save the country when Pakistan’s future is in the hands of such persons. Additionally, Vawda touched on the murder of anchor person Arshad Sharif, claiming that the facts of the case will soon surface. He also commented on PTI founder Imran Khan’s growing awareness of his friends and foes, stating that this realization should have occurred much sooner. Faisal Vawda says that Imran Khan’s eyes are now opening. Read more: Faiz Hameed indicted on charges of political activities, violations of Official Secret Act Earlier, Senator Faisal Vawda claimed that former Director General (DG) Inter Services Intelligence (ISI) Lieutenant General (retd) Faiz Hameed has provided evidence, including devices, against Pakistan Tehreek-e-Insaf (PTI) founder Imran Khan. Speaking during ARY News programme ‘Khabar’, Senator Faisla Vawda said, “The troubles for the PTI founder and his associates are going to be increased as Faiz Hameed has handed over crucial evidence, including devices, against them.” Faisal Vawda said that Faiz Hameed’s trial has deflated the Imran Khan-led party’s call for civil disobedience. “If Faiz Hameed’s trial had not taken place, the PTI founder, his wife, and associates would not have faced these challenges,” he added.The Chicago Bears helped provide just that. Brock Purdy carved up Chicago's defense to lead San Francisco to its best offensive output of the season and the defense dominated the Bears in a 38-13 win Sunday that looked a lot more like the team that went to the Super Bowl last season than the one that has struggled in 2024. “I think just the biggest thing was just getting some energy and momentum,” Purdy said. “This league is hard. It’s tough. If you don’t have momentum or energy and belief within a building, it can be really tough.” The problem for San Francisco (6-7) is it might be too late to salvage its playoff hopes. Three blown fourth-quarter leads to division rivals and the lopsided losses at Green Bay and Buffalo the previous two weeks leave the Niners two games out of the playoffs with only four games to go. They might need to win out to get back to the postseason for a fourth straight season, and even then they could need some help because their three division losses will make it tough to win any tiebreakers in the tightly packed NFC West. “If we win every single game, I think we’ve put ourselves in a very good position to either win the division or somehow sneak our way into playoff contention,” tight end George Kittle said. “I thought everyone’s focused on this one week. ... Forget the whole season whether you’ve played like crap the entire season, whether you’ve had missed opportunities, or whether you have a bunch of touchdowns. Whatever it is, flush all that and just focus on this one game.” Big plays. The Niners repeatedly gashed the Bears for big plays as the passing game looked as good as it has all season. Purdy had eight completions go for at least 20 yards — tied for the most in any game for the 49ers since at least 1991 — with Kittle catching four of them, Isaac Guerendo two and one each for Deebo Samuel and Jauan Jennings. Kickoffs. Jake Moody attempted two line-drive kicks as San Francisco tried to pin Chicago deep instead of allowing a touchback. But both kicks landed shy of the landing zone at the 20, giving the Bears the ball at the 40. DL Yetur Gross-Matos. The Niners have been struggling to generate a pass rush with Nick Bosa sidelined, but Gross-Matos made a big impact on Sunday. He had a career-high three sacks in the game after coming into the game with just one this season. S Ji'Ayir Brown. The second-year safety lost his starting job with the return of Talanoa Hufanga from a wrist injury. Brown played 15 defensive snaps in a spot role and was beat on a TD pass to Rome Odunze in his limited action. Guerendo has a sprained foot and will be evaluated later this week to see if he can play. ... OL Ben Bartch will likely go on IR after suffering a high ankle sprain Sunday. ... LB Dre Greenlaw could return this week for the first time since tearing his Achilles tendon in the Super Bowl. ... DL Nick Bosa (hip, oblique) and LT Trent Williams (ankle) will be evaluated this week but there is no timeline on when they will return. ... LG Aaron Banks cleared the concussion protocol and should play this week. ... LB Dee Winters (ankle), S Malik Mustapha (chest, shoulder) and LB Demetrius Flannigan-Fowles are day-to-day. 305 — The 49ers outgained the Bears by 305 yards in the first half for the ninth best advantage in a first half since at least 1991. The 319 yards for San Francisco were the most by any team in a first half this season and the 4 yards allowed were the fewest. The 49ers host the Los Angeles Rams on Thursday night. AP NFL: https://apnews.com/hub/NFL

For the first time in over two years, the Dallas Cowboys (5-7) will play a game inside AT&T Stadium with the retractable roof open. The roof will be opened for Monday night’s Week 14 home contest against the Cincinnati Bengals (4-8), Jon Machota of The Athletic revealed on social media hours before kickoff. Sunny, 69 degrees in Arlington, TX Roof open for Monday Night Football: Cowboys vs. Bengals pic.twitter.com/1YCZld0Hvl AT&T Stadium is one of five NFL stadiums with a retractable roof. Yet, it hasn’t been open for a Cowboys game since Oct. 30, 2022, a day game against the Chicago Bears (4-9). That was supposed to change when Dallas played on Monday Night Football in Week 11 versus the Houston Texans (8-5). But as the Cowboys were in the process of opening the roof about three hours before kickoff, a piece of sheet metal and some additional small debris fell onto the field . No one was injured. Cowboys going roof open for Week 14 vs. Bengals While assessing the situation, another piece of loose metal was seen stuck in a catwalk. It had to be bolted down before the game and the Cowboys decided to play with the roof closed. Team owner Jerry Jones said the wind gusts that started early afternoon in Arlington and got stronger throughout the day played a role in the piece of sheet metal falling. The Cowboys are 12-11 in their 16 years at AT&T Stadium when the roof and retractable end zone doors are open. They are 2-5 all time with the roof open and doors closed. Dallas is looking for its third consecutive win after a 3-7 start to the season. This article first appeared on 5 GOATs and was syndicated with permission.

Predators aim to energize offense vs. surging Maple LeafsFACT FOCUS: Inspector general’s Jan. 6 report misrepresented as proof of FBI setup

'Grown men would be crying': Detail from Sydney siege Lizzie Pearl can't forgetPASADENA, Calif. , Dec. 9, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that its Board of Directors declared a quarterly cash dividend of $1.32 per common share for the fourth quarter of 2024. The dividend is payable on January 15, 2025 to stockholders of record on December 31, 2024 . The common stock dividend for the year ending December 31, 2024 of $5.19 per common share represents an increase of 23 cents , or 5 percent, over the year ended December 31, 2023 . The dividend allows the company to share its continued high-quality, strong and increasing net cash provided by operating activities with its common stockholders while retaining a significant portion for reinvestment into its pipeline of new Class A/A+ development and redevelopment projects. For the five-year period ending December 31, 2024 , the company expects to generate for reinvestment an aggregate $2.1 billion of net cash provided by operating activities after dividends. 1 Additionally, its dividend payout ratio (quarterly common stock dividends divided by quarterly funds from operations) remains favorably low at 55 percent for the three months ended September 30, 2024. Growth in the company's net cash provided by operating activities continues to generate opportunities to increase the company's quarterly cash dividend per common share while maintaining a low FFO payout ratio. 1 Net cash provided by operating activities after dividends (i) excludes timing differences such as changes in operating assets and liabilities and (ii) includes deductions for distributions to the company's consolidated real estate joint venture partners. Amount represents the years ended December 31, 2020 through 2023 and the midpoint of the company's 2024 guidance range as provided on October 21, 2024. About Alexandria Real Estate Equities, Inc. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 ® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus TM ecosystems in AAA life science innovation cluster locations, including Greater Boston , the San Francisco Bay Area , San Diego , Seattle , Maryland , Research Triangle and New York City . For more information, please visit www.are.com . This press release includes "forward-looking statements" within the meaning of the federal securities laws. Actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the company's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. CONTACT: Sara Kabakoff , Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@are.com View original content to download multimedia: https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-declares-cash-dividend-of-1-32-per-common-share-for-4q24--an-increase-of-2-cents-over-3q24--and-an-aggregate-of-5-19-per-common-share-for-2024--an-increase-of-23-cents-or-5-percent-over-20--302326267.html SOURCE Alexandria Real Estate Equities, Inc.Here’s what a theater lover thinks about the ‘Wicked’ film